Hepion Pharmaceuticals Inc (HEPA)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile

Hepion Pharmaceuticals Inc

Healthcare (1171)

Biotechnology (667)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HEPA's Discussions on Twitter

Vergleichen Sie HEPA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HEPA Hepion Pharmaceuticals Inc	0.0571	0	0	-22.70M	-26.07M	-4.38
VRTX Vertex Pharmaceuticals Inc	450.50	113.52B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	493.22	52.93B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	300.83	39.71B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	585.93	35.00B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	255.86	26.57B	3.81B	-644.79M	-669.77M	-6.24

Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2020-07-20	Fortgesetzt	ROTH Capital	Buy

Hepion Pharmaceuticals Inc Aktie (HEPA) Neueste Nachrichten

Finanzdaten der Hepion Pharmaceuticals Inc-Aktie (HEPA)

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile

Vergleichen Sie HEPA mit anderen Aktien

Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades

Hepion Pharmaceuticals Inc Aktie (HEPA) Neueste Nachrichten

Hepion Pharmaceuticals (HEPA) Gaining Increased Investor Interes - GuruFocus

Hepion Pharmaceuticals (HEPA) Gaining Increased Investor Interest | HEPA Stock News - GuruFocus

Hepion Pharmaceuticals Sells Rencofilstat Patent Assets - TipRanks

Hepion Pharmaceuticals, Inc. SEC 10-Q Report - TradingView

Hepion Pharmaceuticals Delays Form 10-Q Filing - TipRanks

Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting' - MSN

Hepion Pharmaceuticals, Inc.(OTCPK: HEPA) dropped from S&P TMI Index - marketscreener.com

Hepion Pharmaceuticals Announces Receipt of Delisting Notificati - GuruFocus

Hepion Pharmaceuticals (NASDAQ:HEPA) Trading Down 18.8% – Should You Sell? - Defense World

Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: ’Could Get Interesting’ By Stocktwits - Investing.com India

Hepion Pharmaceuticals (HEPA) Faces Nasdaq Delisting, Moves to O - GuruFocus

Hepion Pharmaceuticals (HEPA) to be Delisted from Nasdaq | HEPA Stock News - GuruFocus

Hepion Pharmaceuticals Faces Nasdaq Delisting Notice - TipRanks

Hepion Pharmaceuticals to be delisted from Nasdaq - Investing.com

Hepion Pharmaceuticals to be delisted from Nasdaq By Investing.com - Investing.com India

Hepion Pharmaceuticals Initiates Transition to OTC Markets Following Nasdaq Delisting Notice - Nasdaq

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewswire

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

HEPA Collaborates with New Day Diagnostics on Lucrative Diagnostic Tests | HEPA Stock News - GuruFocus

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC | HEPA Stock News - GuruFocus

Hepion Pharmaceuticals inks deal to license diagnostic tests - Investing.com

Hepion Pharmaceuticals enters binding LOI with New Day Diagnostics - TipRanks

Hepion Pharmaceuticals inks deal to license diagnostic tests By Investing.com - Investing.com Nigeria

Hepion Pharmaceuticals Executes Binding Letter of Intent - GlobeNewswire

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC - Stock Titan

Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing - marketscreener.com

Stocks of Hepion Pharmaceuticals Inc (HEPA) are poised to climb above their peers - Sete News

Financial Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World

HEPA’s 52-Week Rollercoaster: From $0.25 to $79.50 – What’s Next for Investors? - investchronicle.com

Examining HEPA’s book value per share for the latest quarter - uspostnews.com

Press Release Distribution & PR Platform - ACCESS Newswire

Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering - ACCESS Newswire

Holdings of Hepion Pharmaceuticals Inc (HEPA) are aligned with the stars - Sete News

Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Down 2% – What’s Next? - Defense World

Hepion Pharmaceuticals (HEPA) Ends Merger with Pharma Two B - GuruFocus

Hepion Pharmaceuticals (HEPA) Announces $9M Public Offering Laun - GuruFocus

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference - ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Pharma Two B Presents Positive P2B001 Data for Parkinson's Disea - GuruFocus

Hepion Pharmaceuticals (HEPA) to Implement 1-for-50 Reverse Stoc - GuruFocus

Hepion Pharmaceuticals, Inc. SEC 10-K Report - TradingView

HEPA stock touches 52-week low at $0.39 amid sharp annual decline - Investing.com Canada

Is Hepion Pharmaceuticals Inc’s -99.59% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel

Before You Invest, Make Sure You Check This Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Analysis - Stocksregister

Hepion Pharmaceuticals Delays Annual Report Filing - TipRanks

Is Hepion Pharmaceuticals Inc (HEPA) worth investing in despite its undervalued state? - uspostnews.com

Hepion Pharmaceuticals announces 1-for-50 reverse stock split - MSN

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Fall -98.12% In Six Months, Here’s What We Should Expect Now - Marketing Sentinel

HEPA stock plunges to 52-week low, touches $0.67 By Investing.com - Investing.com UK

Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Down 7.2% – Here’s Why - Defense World

Finanzdaten der Hepion Pharmaceuticals Inc-Aktie (HEPA)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie HEPA